Duke logo

Caravaggio for Blood Clots - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if a drug called apixaban is helpful in treating blood clots in people with cancer.

What is the Condition Being Studied?

Blood Thinner for Adults with Blood Clots and Cancer

Who Can Participate in the Study?

Adults who:
- Have been diagnosed with cancer within the last two years
- Have been diagnosed with a blood clot in your leg or lungs
- Have been taking a blood thinner for less than 72 hours

You cannot have a brain tumor or cancer that has spread to your brain to participate in the study.

What is Involved?

If you choose to join this study, you will:

- Be randomly assigned (like the flip of a coin) to take one of two blood thinners, either dalteparin or apixaban
--- Dalteparin is given by a shot once a day
--- Apixaban is a pill that is taken by mouth twice daily
- Return to the clinic for a physical exam, blood tests and vital sign at 4, 12 and 24 weeks after you start study treatment

The total time you will be in the study is 7 months.

Study Details

Full Title
Apixaban for the treatment of Venous Thromboembolism in Patients with Cancer: A Prospective Randomized Open Blinded End-Point (PROBE) Study-The Caravaggio Study
Principal Investigator
Hematologist
Protocol Number
IRB:PRO00091323
NCT:NCT03045406
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698